VYOME HOLDINGS, INC. Research and Development Expense
VYOME HOLDINGS, INC. (HIND) reported Research and Development Expense of $506.72 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- VYOME HOLDINGS, INC. research and development expense for the quarter ending 2026-06-30 was $506.72K, a 532.92% increase year-over-year.
- VYOME HOLDINGS, INC. research and development expense for the quarter ending 2026-03-31 was $666.40K, a 638.25% increase year-over-year.
- VYOME HOLDINGS, INC. research and development expense for the quarter ending 2025-12-31 was $378.25K, a 460.15% increase year-over-year.
- VYOME HOLDINGS, INC. research and development expense for the quarter ending 2025-09-30 was $39.68K, a 40.62% decline year-over-year.
- VYOME HOLDINGS, INC. research and development expense for fiscal 2025 was $588.26K, a 106.12% increase from fiscal 2024.
- VYOME HOLDINGS, INC. research and development expense for fiscal 2024 was $285.39K, a 87.67% decline from fiscal 2023.
- VYOME HOLDINGS, INC. research and development expense for fiscal 2023 was $2.31M, a 8.75% decline from fiscal 2022.
- VYOME HOLDINGS, INC. research and development expense for fiscal 2022 was $2.54M, a 7.09% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $506.72K 10-Q · filed 2026-08-12 | $1.17M 10-Q · filed 2026-08-12 | $1.55M derived: sum of 3 quarters · filed 2026-08-12 | $1.59M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $666.40K 10-Q · filed 2026-05-12 | $1.04M derived: sum of 2 quarters · filed 2026-05-12 | $1.08M derived: sum of 3 quarters · filed 2026-05-12 | $1.16M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $378.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $417.93K derived: sum of 2 quarters · filed 2026-03-18 | $497.99K derived: sum of 3 quarters · filed 2026-08-12 | $588.26K 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $39.68K 10-Q · filed 2025-11-14 | $119.74K derived: sum of 2 quarters · filed 2026-08-12 | $210.01K 10-Q · filed 2025-11-14 | $277.53K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $80.06K 10-Q · filed 2026-08-12 | $476.00K 10-Q · filed 2025-08-14 | $170.33K 10-Q · filed 2026-08-12 | $840.00K 10-Q · filed 2025-08-14 | $237.86K derived: sum of 3 quarters · filed 2026-08-12 | $304.67K derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $90.27K 10-Q · filed 2026-05-12 | $364.00K 10-Q · filed 2025-05-20 | $157.79K derived: sum of 2 quarters · filed 2026-05-12 | $224.61K derived: sum of 3 quarters · filed 2026-05-12 | $623.61K derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $67.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $134.34K derived: sum of 2 quarters · filed 2026-03-18 | $533.34K derived: sum of 3 quarters · filed 2026-03-18 | $285.39K 10-K · filed 2026-03-18 | $1.80M 10-K · filed 2025-04-04 | |||
| 2024-09-30 | $66.81K 10-Q · filed 2025-11-14 | $399.00K 10-Q · filed 2024-11-14 | $465.81K derived: sum of 2 quarters · filed 2025-11-14 | $217.86K 10-Q · filed 2025-11-14 | $1.28M 10-Q · filed 2024-11-14 | $1.69M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $399.00K 10-Q · filed 2025-08-14 | $151.05K 8-K · filed 2025-09-02 | $883.00K 10-Q · filed 2024-08-14 | $1.62M derived: sum of 3 quarters · filed 2025-08-14 | $2.16M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $484.00K 10-Q · filed 2025-05-20 | $1.22M derived: sum of 2 quarters · filed 2025-05-20 | $1.76M derived: sum of 3 quarters · filed 2025-05-20 | $2.35M derived: sum of 4 quarters · filed 2025-05-20 | ||||
| 2023-12-31 | $739.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-04 | $1.28M derived: sum of 2 quarters · filed 2025-04-04 | $1.86M derived: sum of 3 quarters · filed 2025-04-04 | $2.31M 10-K · filed 2025-04-04 | ||||
| 2023-09-30 | $542.00K 10-Q · filed 2024-11-14 | $1.12M derived: sum of 2 quarters · filed 2024-11-14 | $1.58M 10-Q · filed 2024-11-14 | $2.04M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $581.00K 10-Q · filed 2024-08-14 | $1.03M 10-Q · filed 2024-08-14 | $1.50M derived: sum of 3 quarters · filed 2024-08-14 | $2.08M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $453.00K 10-Q · filed 2024-05-15 | $915.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.50M derived: sum of 3 quarters · filed 2024-05-15 | $2.25M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $462.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.04M derived: sum of 2 quarters · filed 2024-04-01 | $1.79M derived: sum of 3 quarters · filed 2024-04-01 | $2.54M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $583.00K 10-Q · filed 2023-11-09 | $588.00K 10-Q · filed 2022-11-14 | $1.33M derived: sum of 2 quarters · filed 2023-11-09 | $2.08M 10-Q · filed 2023-11-09 | $2.10M 10-Q · filed 2022-11-14 | $2.35M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $747.00K 10-Q · filed 2023-08-07 | $761.00K 10-Q · filed 2022-08-19 | $1.49M 10-Q · filed 2023-08-07 | $1.51M 10-Q · filed 2022-08-19 | $1.76M derived: sum of 3 quarters · filed 2023-08-07 | $3.19M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | $745.00K 10-Q · filed 2023-05-15 | $748.00K 10-Q · filed 2022-05-23 | $1.01M derived: sum of 2 quarters · filed 2023-05-15 | $2.44M derived: sum of 3 quarters · filed 2023-05-15 | $2.54M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $270.00K derived: 10-K 12 month − 10-K 9 month · filed 2023-04-17 | $1.70M derived: sum of 2 quarters · filed 2023-04-17 | $1.80M derived: sum of 3 quarters · filed 2023-04-17 | $2.37M 10-K · filed 2023-04-17 | $2.52M 10-K · filed 2022-04-08 | |||
| 2021-09-30 | $1.43M 10-K · filed 2023-04-17 | $1.57M 10-Q · filed 2021-11-12 | $1.53M derived: sum of 2 quarters · filed 2023-04-17 | $2.10M 10-K · filed 2023-04-17 | $2.25M 10-Q · filed 2021-11-12 | $2.98M derived: sum of 4 quarters · filed 2023-04-17 | ||
| 2021-06-30 | $103.00K 10-Q · filed 2022-08-19 | $674.00K 10-Q · filed 2022-08-19 | $1.55M derived: sum of 3 quarters · filed 2022-08-19 | $2.41M derived: sum of 4 quarters · filed 2022-08-19 | ||||
| 2021-03-31 | $571.00K 10-Q · filed 2022-05-23 | $112.00K 10-Q · filed 2021-05-12 | $1.45M derived: sum of 2 quarters · filed 2022-05-23 | $2.31M derived: sum of 3 quarters · filed 2022-05-23 | $2.77M derived: sum of 4 quarters · filed 2022-05-23 | |||
| 2020-12-31 | $879.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | $1.74M derived: sum of 2 quarters · filed 2022-04-08 | $2.20M derived: sum of 3 quarters · filed 2022-04-08 | $3.50M 10-K · filed 2022-04-08 | $2.45M 10-K · filed 2021-03-12 | |||
| 2020-09-30 | $859.00K 10-Q · filed 2021-11-12 | $271.00K 10-Q · filed 2020-11-06 | $1.32M derived: sum of 2 quarters · filed 2021-11-12 | $2.62M 10-Q · filed 2021-11-12 | $2.29M 10-Q · filed 2020-11-06 | $4.07M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $465.00K 10-Q · filed 2021-08-16 | $765.00K 10-Q · filed 2020-07-30 | $1.76M 10-Q · filed 2021-08-16 | $2.02M 10-Q · filed 2020-07-30 | $3.21M derived: sum of 3 quarters · filed 2021-08-16 | $4.39M derived: sum of 4 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $1.26M 10-Q · filed 2021-05-12 | $2.75M derived: sum of 2 quarters · filed 2021-05-12 | $3.92M derived: sum of 3 quarters · filed 2021-05-12 | $5.71M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $2.67M derived: sum of 2 quarters · filed 2021-03-12 | $4.45M derived: sum of 3 quarters · filed 2021-03-12 | $6.89M 10-K · filed 2021-03-12 | ||||
| 2019-09-30 | $1.17M 10-Q · filed 2020-11-06 | $2.96M derived: sum of 2 quarters · filed 2020-11-06 | $5.40M 10-Q · filed 2020-11-06 | $7.74M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $1.79M 10-Q · filed 2020-07-30 | $4.23M 10-Q · filed 2020-07-30 | $6.57M derived: sum of 3 quarters · filed 2020-07-30 | $8.93M derived: sum of 4 quarters · filed 2020-07-30 | ||||
| 2019-03-31 | $2.44M 10-Q · filed 2020-06-19 | $4.78M derived: sum of 2 quarters · filed 2020-06-19 | $7.14M derived: sum of 3 quarters · filed 2020-06-19 | $10.50M derived: sum of 4 quarters · filed 2020-06-19 | ||||
| 2018-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $4.71M derived: sum of 2 quarters · filed 2020-02-27 | $8.06M derived: sum of 3 quarters · filed 2020-02-27 | $10.70M 10-K · filed 2020-02-27 | ||||
| 2018-09-30 | $2.37M 10-Q · filed 2019-11-08 | $5.72M derived: sum of 2 quarters · filed 2019-11-08 | $8.36M 10-Q · filed 2019-11-08 | $11.05M derived: sum of 4 quarters · filed 2019-11-08 | ||||
| 2018-06-30 | $3.35M 10-Q · filed 2019-07-24 | $5.99M 10-Q · filed 2019-07-24 | $8.68M derived: sum of 3 quarters · filed 2019-07-24 | $11.48M derived: sum of 4 quarters · filed 2019-07-24 | ||||
| 2018-03-31 | $2.64M 10-Q · filed 2019-05-10 | $5.33M derived: sum of 2 quarters · filed 2019-05-10 | $8.13M derived: sum of 3 quarters · filed 2019-05-10 | $10.89M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $5.49M derived: sum of 2 quarters · filed 2019-02-22 | $8.25M derived: sum of 3 quarters · filed 2019-02-22 | $10.65M 10-K · filed 2019-02-22 | ||||
| 2017-09-30 | $2.80M 10-Q · filed 2018-11-02 | $5.56M derived: sum of 2 quarters · filed 2018-11-02 | $7.96M 10-Q · filed 2018-11-02 | $10.56M derived: sum of 4 quarters · filed 2018-11-02 | ||||
| 2017-06-30 | $2.76M 10-Q · filed 2018-08-02 | $5.16M 10-Q · filed 2018-08-02 | $7.76M derived: sum of 3 quarters · filed 2018-08-02 | $9.93M derived: sum of 4 quarters · filed 2018-08-02 | ||||
| 2017-03-31 | $2.40M 10-Q · filed 2018-05-10 | $5.00M derived: sum of 2 quarters · filed 2018-05-10 | $7.17M derived: sum of 3 quarters · filed 2018-05-10 | $9.76M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $4.77M derived: sum of 2 quarters · filed 2018-03-05 | $7.36M derived: sum of 3 quarters · filed 2018-03-05 | $9.87M 10-K · filed 2018-03-05 | ||||
| 2016-09-30 | $2.17M 10-Q · filed 2017-11-03 | $4.75M derived: sum of 2 quarters · filed 2017-11-03 | $7.27M 10-Q · filed 2017-11-03 | $11.08M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-06-30 | $2.59M 10-Q · filed 2017-08-02 | $5.10M 10-Q · filed 2017-08-02 | $8.91M derived: sum of 3 quarters · filed 2018-03-05 | $12.11M derived: sum of 4 quarters · filed 2018-03-05 | ||||
| 2016-03-31 | $2.51M 10-Q · filed 2017-05-10 | $6.32M derived: sum of 2 quarters · filed 2018-03-05 | $9.52M derived: sum of 3 quarters · filed 2018-03-05 | |||||
| 2015-12-31 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $7.01M derived: sum of 2 quarters · filed 2018-03-05 | $12.98M 10-K · filed 2018-03-05 | |||||
| 2015-09-30 | $3.20M 10-Q · filed 2016-11-10 | $9.17M 10-Q · filed 2016-11-10 | ||||||
| 2014-12-31 | $5.77M 10-K · filed 2017-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |